消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床观察  

Clinical Observation of Xiaoaiping Injection with Rectum Administration Combined Conventional Chemotherapy in the Treatment of Epithelial Ovarian Tumor

作　　者：李凤霞[1] 宋爱英[1] 唐寅[1] 邹香妮[1] 

机构地区：[1]黑龙江中医药大学附属第一医院,哈尔滨150040

出　　处：《中国药房》2015年第20期2815-2817,共3页China Pharmacy

摘　　要：目的：观察消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌的临床疗效和安全性。方法：选择确诊为上皮性卵巢癌的初诊患者60例,按入院顺序随机分为观察组和对照组各30例。所有患者均接受紫杉醇＋卡铂（TC）化疗方案,共4~6个疗程。其中,对照组患者接受TC 3周化疗方案,即紫杉醇175 mg/m2,静脉滴注3 h＋卡铂AUC 5~7.5,静脉滴注1 h。观察组在此基础上,再经直肠给予消癌平注射液,每次20~30 ml,每日1次,每2周1个周期。比较两组患者的临床有效率、1年无进展生存率和中位无进展生存期,以及不良事件发生率。结果：观察组的有效率为83.33%,高于对照组的53.33%,差异有统计学意义（χ^2=13.20,P〈0.05）;观察组的1年无进展生存率为86.67%,中位无进展生存期为11.3个月,对照组分别为63.33%和7.2个月,组间比较差异有统计学意义（P〈0.01或P〈0.05）。两组不良事件发生率差异无统计学意义（χ^2=0.53,P=0.47）。结论：消癌平注射液直肠给药联合常规化疗治疗上皮性卵巢癌,疗效良好,安全性高,患者1年无进展生存率高,中位无进展生存期长。OBJECTIVE： To observe clinical efficacy and safety of Xiaoaiping injection with rectum administration combined with conventional chemotherapy in the treatment of epithelial ovarian tumor. METHODS： 60 patients diagnosed as epithelial ovari- an tumor were divided into observation group and control group according to the actual order, with 30 cases in each group. AU pa- tients received TC chemotherapy, 4-6 cycles in total; And patients in control group received TC chemotherapy for 3 weeks, i.e. pa- clitaxel 175 mg/mz, 3 h, i.v.＋carboplatin AUC=5-7.5, 1 h, i.v.. Based on this, observation group was additionally given Xiaoaip- ing injection with rectum administration, 20-30 ml each time, once a day, 2 weeks as a treatment course. Clinical effective rate, 1-year progression-free survival rate and median progression free survival and the incidence of adverse events were compared be- tween 2 groups. RESULTS： Effective rate of observation group was 83.33%, and higher than that of control group （53.33%） ; there was statistically significant difference （x^2=13.20, P〈0.05） ; 1-year progression-free survival rate of observation group was 86.67%, and median progression free survival was 11.3 months; those of control group were 63.33% and 7.2 months; there was statistically significant difference between 2 groups （P〈0.01 or P〈0.05）. There was no significant difference in the incidence of ADR between 2 groups （x^2= 0.53, P= 0.47）. CONCLUSIONS ： Xiaoaiping injection with rectum administration combined with con- ventional chemotherapy in the treatment of epithelial ovarian cancer show good curative effect and safety, high 1-year progres- sion-free survival rate and long median progression-free survival.

关 键 词：消癌平注射液 直肠给药 联合化疗 上皮性卵巢癌 

分 类 号：R737.31[医药卫生—肿瘤] R283.61[医药卫生—临床医学]